Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels
Steffan T. Nawrocki et al, 2007, Cancer Research CrossRef
Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
Pierre Autin et al, 2019, Cancers CrossRef
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms
Sharmila Shankar et al, 2008, Molecular Cancer Therapeutics CrossRef
Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
Mohammed I. Y. Elmallah et al, 2019, Cancers CrossRef
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari et al, 2021, Journal of Medicinal Chemistry CrossRef
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Maria Mrakovcic et al, 2019, International Journal of Molecular Sciences CrossRef
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Alessandra Zingoni et al, 2017, Frontiers in Immunology CrossRef
Epigenetic Metalloenzymes
Christophe Blanquart et al, 2019, Current Medicinal Chemistry CrossRef
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Rehmat Jan et al, 2019, Advanced Pharmaceutical Bulletin CrossRef
Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis
Sharmila Shankar et al, 2008, Clinical Cancer Research CrossRef
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
Ilker Y. Eyüpoglu et al, 2006, Molecular Cancer Therapeutics CrossRef
Interactive Effects of HDAC Inhibitors and TRAIL on Apoptosis Are Associated with Changes in Mitochondrial Functions and Expressions of Cell Cycle Regulatory Genes in Multiple Myeloma
Tamer E. Fandy et al, 2005, Neoplasia CrossRef